IN2014MN01493A - - Google Patents
Info
- Publication number
- IN2014MN01493A IN2014MN01493A IN1493MUN2014A IN2014MN01493A IN 2014MN01493 A IN2014MN01493 A IN 2014MN01493A IN 1493MUN2014 A IN1493MUN2014 A IN 1493MUN2014A IN 2014MN01493 A IN2014MN01493 A IN 2014MN01493A
- Authority
- IN
- India
- Prior art keywords
- oligonucleotides
- modulating
- present
- gene
- tumoural
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
The present invention regards oligonucleotides for modulating the expression of a gene in particular for modulating a gene responsible for a pathology of genetic tumoural or viral origin. Moreover the present invention relates to the use of said oligonucleotides possibly chemically modified for the treatment and/or the diagnosis of said diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000275A ITMI20120275A1 (en) | 2012-02-24 | 2012-02-24 | OLIGONUCLEOTIDS FOR THE MODULATION OF GENE EXPRESSION AND THEIR USES |
| PCT/IB2013/051410 WO2013124807A2 (en) | 2012-02-24 | 2013-02-21 | Oligonucleotides for modulating gene expression and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01493A true IN2014MN01493A (en) | 2015-04-17 |
Family
ID=45999941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1493MUN2014 IN2014MN01493A (en) | 2012-02-24 | 2013-02-21 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10023867B2 (en) |
| EP (1) | EP2817407B1 (en) |
| JP (2) | JP6333739B2 (en) |
| KR (1) | KR101992925B1 (en) |
| CN (2) | CN115216475A (en) |
| AR (1) | AR090129A1 (en) |
| AU (2) | AU2013223694B2 (en) |
| BR (1) | BR112014020885B1 (en) |
| CA (1) | CA2864060C (en) |
| CY (1) | CY1120084T1 (en) |
| DK (1) | DK2817407T3 (en) |
| ES (1) | ES2651147T3 (en) |
| HK (1) | HK1201878A1 (en) |
| HU (1) | HUE034846T2 (en) |
| IN (1) | IN2014MN01493A (en) |
| IT (1) | ITMI20120275A1 (en) |
| LT (1) | LT2817407T (en) |
| MA (1) | MA35935B1 (en) |
| NO (1) | NO2817407T3 (en) |
| PL (1) | PL2817407T3 (en) |
| PT (1) | PT2817407T (en) |
| RS (1) | RS56631B1 (en) |
| RU (1) | RU2648140C2 (en) |
| SG (2) | SG10201606946YA (en) |
| SI (1) | SI2817407T1 (en) |
| SM (1) | SMT201800042T1 (en) |
| TN (1) | TN2014000327A1 (en) |
| WO (1) | WO2013124807A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20120275A1 (en) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | OLIGONUCLEOTIDS FOR THE MODULATION OF GENE EXPRESSION AND THEIR USES |
| US20150152410A1 (en) | 2012-05-16 | 2015-06-04 | Rana Therapeutics, Inc. | Compositions and methods for modulating mecp2 expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| JP2015518710A (en) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | Compositions and methods for regulating hemoglobin gene family expression |
| EA201492123A1 (en) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF THE SMN GENES FAMILY |
| EA201492122A1 (en) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR MODULATING UTRN EXPRESSION |
| AU2013262699A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating ATP2A2 expression |
| CN110392581A (en) * | 2016-12-13 | 2019-10-29 | 阿姆科学有限公司 | For preventing or treating the pharmaceutical composition of hepatitis B |
| EP4497432A4 (en) * | 2022-03-22 | 2025-07-30 | Bion Inc | Protein release composition containing bile salt and cationic peptide and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU756301B2 (en) * | 1997-08-20 | 2003-01-09 | Somagenics, Inc. | Antisense and antigene therapeutics with improved binding properties and methods for their use |
| CA2400028A1 (en) * | 2000-02-14 | 2001-08-23 | Arthur P. Bollon | Libraries of optimum subsequence regions of mrna and genomic dna for control of gene expression |
| JP2004524371A (en) * | 2001-04-13 | 2004-08-12 | ザ・ポピュレイション・カウンシル，インコーポレイテッド | Introduction of peptide nucleic acid into cell nucleus via nuclear receptor |
| WO2002092617A1 (en) | 2001-05-17 | 2002-11-21 | Avi Biopharma, Inc. | Combined approach to treatment of cancer using a c-myc antisense oligomer |
| EP1448590A4 (en) * | 2002-02-20 | 2004-12-15 | Sirna Therapeutics Inc | Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways |
| ITMI20030860A1 (en) * | 2003-04-29 | 2004-10-30 | Univ Bologna | METHOD FOR SELECTIVE INHIBITION OF THE N-MYC GENE |
| WO2005045032A2 (en) * | 2003-10-20 | 2005-05-19 | Sima Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF EARLY GROWTH RESPONSE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| GB0415263D0 (en) * | 2004-07-07 | 2004-08-11 | Norwegian Radium Hospital Res | Method |
| RU2007119313A (en) * | 2004-10-25 | 2008-11-27 | Новартис АГ (CH) | TORC POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF APPLICATION |
| CA2631931C (en) * | 2005-12-01 | 2014-04-29 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
| US7625874B2 (en) * | 2006-04-11 | 2009-12-01 | The Regents Of The University Of California | Compositions and methods for treating diseases associated with T-box and N-Myc |
| US20080038783A1 (en) * | 2006-06-29 | 2008-02-14 | Applera Corporation | Compositions and Methods Pertaining to Guanylation of PNA Oligomers |
| WO2009009739A2 (en) * | 2007-07-12 | 2009-01-15 | Theracrine, Inc. | Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer |
| US20110105422A1 (en) * | 2008-02-05 | 2011-05-05 | Gary Acton | Use of g-rich oligonucleotides for treating neoplastic diseases |
| KR101866152B1 (en) * | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| CN102058535B (en) * | 2010-12-21 | 2013-05-01 | 中国人民解放军总医院 | Novel folate receptor targeted liposome |
| ITMI20120275A1 (en) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | OLIGONUCLEOTIDS FOR THE MODULATION OF GENE EXPRESSION AND THEIR USES |
-
2012
- 2012-02-24 IT IT000275A patent/ITMI20120275A1/en unknown
-
2013
- 2013-02-21 SM SM20180042T patent/SMT201800042T1/en unknown
- 2013-02-21 AU AU2013223694A patent/AU2013223694B2/en active Active
- 2013-02-21 KR KR1020147026837A patent/KR101992925B1/en active Active
- 2013-02-21 DK DK13716415.8T patent/DK2817407T3/en active
- 2013-02-21 PL PL13716415T patent/PL2817407T3/en unknown
- 2013-02-21 NO NO13716415A patent/NO2817407T3/no unknown
- 2013-02-21 CA CA2864060A patent/CA2864060C/en active Active
- 2013-02-21 CN CN202210708144.7A patent/CN115216475A/en active Pending
- 2013-02-21 JP JP2014558247A patent/JP6333739B2/en active Active
- 2013-02-21 EP EP13716415.8A patent/EP2817407B1/en active Active
- 2013-02-21 ES ES13716415.8T patent/ES2651147T3/en active Active
- 2013-02-21 BR BR112014020885-9A patent/BR112014020885B1/en active IP Right Grant
- 2013-02-21 RS RS20171253A patent/RS56631B1/en unknown
- 2013-02-21 SG SG10201606946YA patent/SG10201606946YA/en unknown
- 2013-02-21 HK HK15102407.6A patent/HK1201878A1/en unknown
- 2013-02-21 SG SG11201404852WA patent/SG11201404852WA/en unknown
- 2013-02-21 LT LTEP13716415.8T patent/LT2817407T/en unknown
- 2013-02-21 RU RU2014138198A patent/RU2648140C2/en active
- 2013-02-21 HU HUE13716415A patent/HUE034846T2/en unknown
- 2013-02-21 CN CN201380009360.1A patent/CN104169421A/en active Pending
- 2013-02-21 US US14/379,729 patent/US10023867B2/en active Active
- 2013-02-21 SI SI201330845T patent/SI2817407T1/en unknown
- 2013-02-21 PT PT137164158T patent/PT2817407T/en unknown
- 2013-02-21 IN IN1493MUN2014 patent/IN2014MN01493A/en unknown
- 2013-02-21 WO PCT/IB2013/051410 patent/WO2013124807A2/en not_active Ceased
- 2013-02-22 AR ARP130100546A patent/AR090129A1/en active IP Right Grant
-
2014
- 2014-07-31 TN TNP2014000327A patent/TN2014000327A1/en unknown
- 2014-09-10 MA MA37342A patent/MA35935B1/en unknown
-
2017
- 2017-12-05 CY CY20171101270T patent/CY1120084T1/en unknown
- 2017-12-12 JP JP2017237889A patent/JP2018078893A/en active Pending
-
2018
- 2018-06-15 US US16/009,303 patent/US10752900B2/en active Active
- 2018-12-13 AU AU2018278972A patent/AU2018278972A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01493A (en) | ||
| PH12019502292A1 (en) | Methods and compositions for treatment of a genetic condition | |
| MX356525B (en) | Aav -vectors for use in gene therapy of choroideremia. | |
| MX2012003770A (en) | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products. | |
| IL265774B (en) | Diagnosis, prevention and treatment of diseases of the joint | |
| NZ704039A (en) | Cell-free dna as a therapeutic target for female infertility and diagnostic marker | |
| WO2014055790A9 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| PH12014501702A1 (en) | Imidazopyrrolidinone compounds | |
| GEP20156347B (en) | Benzodioxane inhibitors of leukotriene production | |
| MX357656B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases. | |
| SG10201703677VA (en) | Methods of treating s. aureus-associated diseases | |
| EP3052191A4 (en) | Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als) | |
| PH12015500663A1 (en) | Pharmaceutical combinations comprising dual angiopoietin-2/dll4 binders and anti-vegf-r agents | |
| EP3135766A4 (en) | Aptamer for bonding to autotaxin and inhibiting biological activity of autotaxin, and use for same | |
| IL239078A0 (en) | Protein for use in the treatment of ocular diseases | |
| BR112013016878A2 (en) | DNA involved in regulating gene expression in photosynthetic tissue. | |
| UA61823U (en) | Use of gamma-butyric acid for stimulating regeneration and restoring strength of muscular contractions |